Answer:
The change in the genes p53 and p21 results in deficits in checkpoints that result in cancer of various types. The G2-HM checkpoint deficits can be exploited in the development of targeted treatment.
A mutation in the above normal functioning of p53 can lead to the progression of damaged cells to mitosis which leads to cancer. So therapeutics which target any of these checkpoints can lead to developing a treatment for cancer.